Cellebrite DI Ltd. $CLBT Shares Sold by Royal Bank of Canada

Royal Bank of Canada decreased its holdings in Cellebrite DI Ltd. (NASDAQ:CLBT) by 16.3% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,026,309 shares of the company’s stock after selling 200,251 shares during the period. Royal Bank of Canada owned approximately 0.41% of Cellebrite DI worth $14,142,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Roubaix Capital LLC raised its stake in shares of Cellebrite DI by 108.1% in the 1st quarter. Roubaix Capital LLC now owns 303,215 shares of the company’s stock valued at $4,178,000 after acquiring an additional 157,536 shares during the period. Lazard Asset Management LLC purchased a new stake in Cellebrite DI during the 1st quarter worth $2,134,000. Principal Financial Group Inc. increased its holdings in Cellebrite DI by 33.9% in the 1st quarter. Principal Financial Group Inc. now owns 2,156,166 shares of the company’s stock valued at $29,712,000 after purchasing an additional 545,334 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its holdings in Cellebrite DI by 28.6% in the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,350,000 shares of the company’s stock valued at $24,341,000 after purchasing an additional 300,000 shares in the last quarter. Finally, Weiss Asset Management LP raised its position in Cellebrite DI by 3,485.3% in the first quarter. Weiss Asset Management LP now owns 1,899,841 shares of the company’s stock valued at $26,180,000 after purchasing an additional 1,846,851 shares during the period. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CLBT has been the topic of a number of recent research reports. Weiss Ratings upgraded Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 18th. Needham & Company LLC dropped their target price on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Finally, DA Davidson boosted their price target on Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday. Five investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $21.80.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $16.01 on Friday. Cellebrite DI Ltd. has a 12-month low of $11.02 and a 12-month high of $19.98. The company has a market capitalization of $3.99 billion, a price-to-earnings ratio of 57.18, a price-to-earnings-growth ratio of 1.92 and a beta of 1.18. The firm’s fifty day moving average price is $14.55 and its 200 day moving average price is $14.11.

Insider Transactions at Cellebrite DI

In related news, CFO David Barter sold 41,734 shares of the business’s stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $16.38, for a total value of $683,602.92. Following the transaction, the chief financial officer owned 334,219 shares in the company, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Thomas E. Hogan sold 103,188 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total value of $1,626,242.88. Following the completion of the transaction, the chief executive officer directly owned 590,777 shares of the company’s stock, valued at $9,310,645.52. This represents a 14.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 158,191 shares of company stock valued at $2,479,438. 5.70% of the stock is currently owned by insiders.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.